Wet AMD

Investigators corroborate the hypothesis that retinal ganglion cells with dendrites stratified in the off sublaminae could be damaged.

Amid pandemic, physicians and patients have embraced remote technology.

An updated PDS procedure reduces complications.

The not-for-profit vision and healthcare organization breaks ground on premier Technology Center for assistive technology for people with vision loss.

The company is hoping to commercialize the first FDA-approved ophthalmic formulation of bevacizumab-vikg for retinal disease. It expects to receive BLA approval from the FDA by mid-2022.

EYS809, a non-viral gene therapy sustained drug-delivery product that delivers anti-vascular endothelial growth factor to the eye, may replace the need for repeated intravitreal anti-VEGF injections and improve vision in patients diagnosed with wet age-related macular degeneration.

This novel intravitreal gene therapy may also hold potential for the treatment of diabetic macular edema.

Injections and implants continue to create further positive outcomes for patients.

Novel option demonstrates stable to improved visual acuity and retinal thickness

Minimizing clinic visits, maximizing use of imaging modalities are key

Rapid fluid identification may result in better visual outcomes

Specialist explains approaches for a variety of cases encountered during procedure

Anat Loewenstein, MD, provides an update on the latest developments in emerging therapies for the management of age-related macular degeneration (AMD) and wet AMD.

Joshua Mali, MD, discusses the three major risk factors for developing age-related macular degeneration (AMD).

Ian C. Han, MD, dives into the basics of age-related macular degeneration (AMD) and what patients need to know.

Rishi P. Singh, MD, highlights various treatment options available for the management of patients with age-related macular degeneration, as well as the status of potential therapies.

Analyses of IRIS Registry data capture a snapshot of patient visits and receipt of anti-VEGF injections.

Prospective randomized trial demonstrates clinical equivalence of biosimilar and reference ranibizumab

Phase 1b data show improved vision and reduced macular edema in patients, with only 3 loading doses and minimal re-treatments.

Manufacturers are stepping up to design products that will help maximize the safety and efficiency of intravitreal injection.

Investigational OCT system with AI-based image analysis holds promise

An interim analysis including data from almost 150 patients found an association between higher number of injections and increased risk of mild cognitive impairment.

Interim data update from first cohort using suprachoroidal delivery of RGX-314 expected by end of 2020

Results of a prospective trial show the tool is ready for clinical use and potential deployment for remote telemedical use.

A study suggests this user-friendly platform may be useful as a supplemental visual function measure in patients with AMD.

The number of patients with retinal diseases is steadily increasing in the United States, according to a retrospective study presented during ARVO 2020.

Early detection and anti-VEGF treatment of choroidal neovascularization (CNV) in the second eye leads to better mean final visual acuity (VA) with fewer injections at 1 year.

S.K. Steven Houston III, MD, discusses retina innovations in use in his practice, including the NGENUITY 1.4 upgrade from Alcon, and adapting to ever-changing operating room spacing and set-up in the COVID-19 environment